Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of

Immunicum's Approach Activating the immune system against solid and blood-borne cancers The most exciting developments in cancer treatment today involve medicines that activate a patient’s own immune system to destroy cancer cells, known as cancer immunotherapy or the field of immuno-oncology.

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, At the Annual General Meeting of Immunicum AB (publ), reg. no 556629-1786, on April 25, 2019 the AGM adopted, inter alia, the following resolutions. Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic 2021-02-19 08:00:00 Other information disclosed according to the rules of the Exchange, Immunicum AB (publ) Receives Orphan Drug Designation from EMA Immunicum is a clinical phase II company, develops cancer immunotherapies. Status Active; Last Funding Type Post-IPO Equity; Legal Name Immunicum AB. Immunicum AB (Nasdaq Stockholm: https://t.co/flpMTI73nE) is a clinical stage company developing novel #immunooncology therapies against a range of solid IMMU | Complete Immunicum AB stock news by MarketWatch.

Immunicum ab

New Tanken är att ICOpre ska bli ett AB-klassat (terapeutiskt ekvivalent) substitut för GSKs Ellipta-portfölj som för närvarande består av fem inhalationsprodukter: ÅAC Microtec AB BTA · AAK · Aallon Group Oyj · Aarhus Karlshamn Immunicum · Immunovia · Impact Coatings · Implantica · Implementa ÅAC Microtec AB BTA · AAK · Aallon Group Oyj · Aarhus Karlshamn Immunicum · Immunovia · Impact Coatings · Implantica · Implementa 201. Immunicum - IMMU (17) · Shawiee. Svar av BuffWett 2021-04-25 00:09 160. TerraNet Holding AB (14) · notebook. Svar av Assault12 2021-04-23 08:46.

Click to view STO:IMMU's StockReport. IMMUNICUM AB (PUBL).

Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trials

Tel: +46 (0)8 732 8400. Feb 9, 2021 Immunicum is planning to move its in-house research and process development activities into a new facility at the Leiden Bio Science Park. Dec 16, 2020 Immunicum AB (publ; IMMU.ST) published today the Company's financial calendar for the year of 2021.

Immunicum AB. Last updated: 10.07.2019. company_picture. immunicum. Address: Östermalmstorg 5, 114 42 Stockholm, Sweden. Tel: +46 (0)8 732 8400.

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).

Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic 2021-02-19 08:00:00 Other information disclosed according to the rules of the Exchange, Immunicum AB (publ) Receives Orphan Drug Designation from EMA Immunicum is a clinical phase II company, develops cancer immunotherapies. Status Active; Last Funding Type Post-IPO Equity; Legal Name Immunicum AB. Immunicum AB (Nasdaq Stockholm: https://t.co/flpMTI73nE) is a clinical stage company developing novel #immunooncology therapies against a range of solid IMMU | Complete Immunicum AB stock news by MarketWatch.
Toveks personbilar

Telefon: +49 171 351 2733. E-post: ir@immunicum.com. OM IMMUNICUM AB (PUBL) Immunicum tillämpar sin framstående expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims … Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer.

no 556629-1786, on April 25, 2019 the AGM adopted, inter alia, the following resolutions.
Star a aktie

Immunicum AB (publ) planerar att expandera bolagets anläggning för forskning och processutveckling i Leiden, Nederländerna. 2021-01-27. Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands. Fler pressmeddelanden.

IMMUNICUM: ERIK MANTING NY VD, SVEN ROHMANN KVAR SOM RÅDGIVARE.